About Viome Life Sciences
Viome Life Sciences is a company based in Bothell (United States) founded in 2016 by Momchilo Momo Vuyisich and Naveen Jain. Viome Life Sciences has raised $92.44 million across 2 funding rounds from investors including Khosla Ventures, Glico Group and BOLD Capital Group. Viome Life Sciences offers products and services including Diagnostic Tests, Precision Nutrition, Predictive Biomarkers, and Therapeutics Development. Viome Life Sciences operates in a competitive market with competitors including Prometheus Laboratories, InDex Pharmaceuticals, NinePoint Medical, Proteomics International and Given Imaging, among others.
- Total Equity Funding$92.44M (USD)
in 2 rounds
- Latest Funding Round$25.44M (USD), Series C
Aug 2024
- InvestorsKhosla Ventures
& 5 more
Products & Services of Viome Life Sciences
Viome Life Sciences offers a comprehensive portfolio of products and services, including Diagnostic Tests, Precision Nutrition, Predictive Biomarkers, and Therapeutics Development.
Analyzes RNA for predictive health insights and chronic disease detection.
Provides tailored nutrition plans based on microbiome data for wellness.
Identifies disease signatures through microbial analysis for early intervention.
Develops drugs and vaccines targeting microbiome-related conditions.
Apps and channels of Viome Life Sciences
its YouTube channel Viome has 6.86K subscribers and 30 videos.
Videos from Viome Life Sciences
The most watched videos on Viome Life Sciences's YouTube channel, Viome (6.86K subscribers). Click a video to play it here.
More on Viome.
Funding Insights of Viome Life Sciences
Viome Life Sciences has successfully raised a total of $92.44M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $25.44 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92.44M
- Total Rounds 2
- Last Round Series C — $25.44M
- First Round $67M
(Oct 2022)
- Investors Count 6
All 2 funding rounds of Viome Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $25.44M | Series C | – | – | – |
| Oct 2022 | $67M | Series C | – | BOLD Capital Group |
6 investors in total: 6 institutional.
Investors in Viome Life Sciences
Viome Life Sciences has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Khosla Ventures, Glico Group and BOLD Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Investments are focused across multiple sectors by the firm. | – | wrg.vc | Seattle, United States | |
Venture capital is invested in companies across multiple sectors. | – | ocgrowgroup.com | Calgary, Canada | |
Privately owned firm providing investments and advisory for tech platforms. | 2019 | boldcapitalgroup.com | Charleston, United States | |
Chocolate brand | 1922 | glico.com | Osaka, Japan | |
Better Health Group is focused on transforming sick care into value-based primary care. | – | phypartners.com | Tampa, United States |
Investor details for Viome Life Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Viome Life Sciences
40 people are tracked at Viome Life Sciences (13 in leadership, 13 in board & advisors, 14 in team).
| Name | Role | Group |
|---|---|---|
Momchilo Momo Vuyisich | Co-Founder & Chief Science Officer | Leadership |
Naveen Jain | Founder & CEO | Leadership |
Guruduth Banavar | Founding CTO & Head of Discovery AI | Leadership |
Damon Tanton | Chief Medical Officer | Leadership |
Stephen Barrie | VP & Head of Clinical Nutrition | Leadership |
Helene Vollbracht | Chief Product Strategy Officer, Corporate Brand & Communications | Leadership |
Anel Visser | Lab Director | Leadership |
Oliver Solano | Director Of Software Engineering | Leadership |
Jim Fuller Ph.D., Dabcc, Faacc | Clinical Laboratory Director | Leadership |
Lisa Shomo | Head Of Community | Leadership |
Jessica Youngblood | Vp, Product Operations & Strategy | Leadership |
Angel Janevski | Head Of Data And Analytics Solutions | Leadership |
Ed Billmaier | Vice President Customer Experience | Leadership |
Emeran Mayer | Scientific Advisory Board Member | Board & advisors |
Alessio Fasano | Scientific Advisory Board Member | Board & advisors |
Andrew McCallum | Scientific Advisory Board Member | Board & advisors |
Umadevi Naidoo | Director | Board & advisors |
Chris Kitze | Director | Board & advisors |
Erik Anderson | Director | Board & advisors |
Sanjiv Chopra | Scientific Advisory Board Member | Board & advisors |
20 more people are available in the full profile.
Complete people profiles for Viome Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Viome Life Sciences
3 dated milestones of Viome Life Sciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Viome Life Sciences is founded.
- Funding First funding round of $67.0M.
- Funding Latest funding round, Series C, of $25.4M.
Competitors of Viome Life Sciences
Viome Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prometheus Laboratories, InDex Pharmaceuticals, NinePoint Medical, Proteomics International and Given Imaging, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prometheuslabs.com | 1995 | San Diego, United States | – | 474 | Diagnostics and therapeutics for gastrointestinal and personalized medicine are developed. | |
| indexpharma.com | 2000 | Stockholm, Sweden | $45.42M | – | DNA-based immunomodulatory drugs for ulcerative colitis are developed. | |
| ninepointmedical.com | 2008 | Bedford, United States | $98.26M | 25 | Optical coherence tomography systems for tissue microstructure imaging are developed. | |
| proteomics.com.au | 2001 | Perth, Australia | – | – | Medical technology company at the forefront of predictive diagnostics and bio-analytical services | |
| givenimaging.com | 1998 | Minneapolis, United States | – | – | Capsule endoscopy systems for GI imaging | |
| enterasense.com | 2016 | Galway, Ireland | $1.14M | – | Ingestible biosensor for GI disease | |
| tethysbio.com | 2002 | Emeryville, United States | $53.3M | 81 | Develops biological markers for medical diagnostic applications. | |
| vigilantbiosciences.com | 2011 | Fort Lauderdale, United States | $29.76M | – | Solutions for early oral cancer detection are developed and provided. | |
| erlysign.com | 2019 | Nagpur, India | $2.17M | – | A platform providing test kits for detecting oral cancer |
Detailed competitors of Viome Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Viome Life Sciences
The website of Viome Life Sciences (viomelifesciences.com) receives about 4.9K visits a month.
- Monthly visits4.9K
▲ 7.9% vs previous month
Latest news on Viome Life Sciences
Complete news archive for Viome Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Viome Life Sciences
10 companies that operate in the same segment as Viome Life Sciences (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 245.2 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Viome Life Sciences
Viome Life Sciences was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Viome Life Sciences is headquartered in Bothell, United States. It is registered at Bothell, Washington, United States.
Naveen Jain is the current CEO of Viome Life Sciences. They have also founded this company.
Viome Life Sciences is a funded company, having raised a total of $92.44M across 2 funding rounds to date. The company's 1st funding round was a Series C of $67M, raised on Oct 2022.
Provider of tests to prevent, treat, and cure chronic diseases, and cancer. It uses AI and proprietary mRNA sequencing technology to develop a CancerDetect test for oral throat cancer. The company platform enables to development of predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases. It has also developed 30 predictive models for Glycemic response, Obesity, Diabetes, Depression, IBS, and Oral Cancer.
Viome Life Sciences's top competitors include Prometheus Laboratories, NinePoint Medical and Proteomics International.
Viome Life Sciences offers Diagnostic Tests, Precision Nutrition, Predictive Biomarkers, and Therapeutics Development.
Viome Life Sciences has 6 investors. Key investors include Khosla Ventures, Glico Group, BOLD Capital Group, WestRiver Group, and Ocgrow Group of Companies.
Viome Life Sciences operates through Viome Life Sciences, Inc..